

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.2050000APPLICATION NO.
097529,659APPLICANT
Wagner et al.102(e) DATE
June 22, 2000

GROUP

1643/642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL1	WO 93/07906	04/29/1993	WIPO			Yes No
	AM1	WO 93/10219	05/27/1993	WIPO			Abstract Yes No
	AN1	WO 94/21808	09/29/1994	WIPO			Abstract Yes No
	AO1	WO 95/09655	04/13/1995	WIPO			Yes No
	AP1	DE 44 11 425 A1	10/19/1995	Germany			Abstract Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	1	Barth, A., et al., "Polyvalent Melanoma Cell Vaccine Induces Delayed-Type Hypersensitivity and In Vitro Cellular Immune Response," <i>Cancer Res.</i> 54:3342-3345 (1994).
	AS	1	Belli, F., et al., "Active Immunization of Metastatic Melanoma Patients with Interleukin-2-Transduced Allogeneic Melanoma Cells: Evaluation of Efficacy and Tolerability," <i>Cancer Immunol. Immunother.</i> 44:197-203 (June 1997).
	AT	1	Berd, D., et al., "Treatment of Metastatic Melanoma with an Autologous Tumor-Cell Vaccine: Clinical and Immunologic Results in 64 Patients," <i>J. Clin. Oncol.</i> 8:1858-1867 (1990).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
NOV 09 2000

Page 2 of 16
NOV 07 2000
TRADEMARK OFFICE

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.2050000

APPLICATION NO.
09/529,659

APPLICANT
Wagner et al.

102(e) DATE
June 22, 2000

GROUP
1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
BB ↓	AL2	WO 95/31107	11/23/1995	WIPO			Yes No
	AM2	WO 97/30721	08/28/1997	WIPO			Abstract Yes No
	AN2	DE 196 07 044 A1	08/28/1997	Germany			Abstract Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

BB ↓	AR	2	Bergers, J.J., et al., "Vesicles for Tumour-Associated Antigen Preparation to Induce Protective Immunity: Preparation, Characterization and Enhancement of the Immune Response by Immunomodulators," <i>J. Controlled Release</i> 29:317-327 (1994).
	AS	2	Buschle, M., et al., "Transloading of Tumor Antigen-Derived Peptides into Antigen-Presenting Cells," <i>Proc. Natl. Acad. Sci.</i> 94:3256-3261 (April 1997).
	AT	2	Clary, B.M., et al., "Inhibition of Established Pancreatic Cancers Following Specific Active Immunotherapy with Interleukin-2 Gene-Transduced Tumor Cells," <i>Cancer Gene Ther.</i> 4:97-104 (March-April 1997).

EXAMINER

Pansal

DATE CONSIDERED

8/19/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.2050000APPLICATION NO.
09/529,659APPLICANT
Wagner *et al.*102(e) DATE
June 22, 2000

GROUP

1645 1642



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	3	Clary, B.M., <i>et al.</i> , "Active Immunotherapy of Pancreatic Cancer with Tumor Cells Genetically Engineered to Secrete Multiple Cytokines," <i>Surgery</i> 120:174-181 (August 1996).
	AS	3	Cleland, J.L., and Jones, A.J.S., "Stable Formulations of Recombinant Human Growth Hormone and Interferon- γ for Microencapsulation in Biodegradable Microspheres," <i>Pharm. Res.</i> 13:1464-1475 (October 1996)
	AT	3	Dranoff, G., <i>et al.</i> , "Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity," <i>Proc. Natl. Acad. Sci. USA</i> 90:3539-3543 (1993).

EXAMINER


DATE CONSIDERED

8/19/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.2050000APPLICATION NO.
09/529,659APPLICANT
Wagner *et al.*102(e) DATE
June 22, 2000GROUP
4643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	4	Eppstein, D.A., "Altered Pharmacologic Properties of Liposome-Associated Human Interferon-Alpha. II," <i>J. Interferon Res.</i> 2:117-125 (1982).
	AS	4	Fearon, E.R., <i>et al.</i> , "Interleukin-2 Production by Tumor Cells Bypasses T Helper Function in the Generation of an Antitumor Response," <i>Cell</i> 60:397-403 (1990).
	AT	4	Ferrantini, M., <i>et al.</i> , "IFN- α 1 Gene Expression Into a Metastatic Murine Adenocarcinoma (TS/A) Results in CD8+ T Cell-Mediated Tumor Rejection and Development of Antitumor Immunity. Comparative Studies with IFN- γ -Producing TS/A Cells," <i>J. Immunol.</i> 153:4604-4615 (1994).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
NOV 09 2000
PATENT CENTER

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT


ATTY. DOCKET NO.
0652.2050000

PUBLICATION NO.
09/529,659

APPLICANT
Wagner *et al.*

102(e) DATE
June 22, 2000

GROUP
1643



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	5	Fujiwara, T., <i>et al.</i> , "Application of An Interleukin 2 Slow Delivery System to the Immunotherapy of Established Murine Colon 26 Adenocarcinoma Liver Metastases," <i>Cancer Res.</i> 50:7003-7007 (1990).
	AS	5	Gansbacher, B., <i>et al.</i> , "Interleukin 2 Gene Transfer into Tumor Cells Abrogates Tumorigenicity and Induces Protective Immunity," <i>J. Exp. Med.</i> 172:1217-1224 (1990).
	AT	5	Golumbek, P.T., <i>et al.</i> , "Controlled Release, Biodegradable Cytokine Depots: A New Approach in Cancer Vaccine Design," <i>Cancer Res.</i> 53:5841-5844 (1993).

EXAMINER


DATE CONSIDERED

8/19/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.2050000APPLICATION NO.
09/529,659APPLICANT
Wagner *et al.*102(e) DATE
June 22, 2000GROUP
1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	6	Herrmann, J., <i>et al.</i> , "Interferon- γ Liposomes: Drug Binding Properties and Antiviral <i>in vitro</i> Activity," <i>Eur. J. Pharm. Biopharm.</i> 41:361-368 (1995).
	AS	6	Jaffee, E.M., <i>et al.</i> , "Enhanced Immune Priming with Spatial Distribution of Paracrine Cytokine Vaccines," <i>J. Immunother.</i> 19:176-183 (May 1996).
	AT	6	Johnson, O.L., <i>et al.</i> , "A Month-long Effect from a Single Injection of Microencapsulated Human Growth Hormone," <i>Nature Med.</i> 2:795-799 (July 1996).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


8/19/01

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.2050000APPLICATION NO.
09/529,659APPLICANT
Wagner *et al.*102(e) DATE
June 22, 2000GROUP
1643

1642



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	Z	Kedar, E., <i>et al.</i> , "Delivery of Cytokines by Liposomes. I. Preparation and Characterization of Interleukin-2 Encapsulated in Long-circulating Sterically Stabilized Liposomes," <i>J. Immunother.</i> 16:47-59 (1994).
	AS	Z	Lamont, A.G., and Adorini, L., "IL-12: A Key Cytokine in Immune Regulation," <i>Immunol. Today</i> 17:214-217 (May 1996).
	AT	Z	Lee, H.J., <i>et al.</i> , "In Vivo Characterization of Sustained-release Formulations of Human Growth Hormone," <i>J. Pharmacol. Exp. Ther.</i> 281:1431-1439 (June 1997).

EXAMINER

DATE CONSIDERED

8/19/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.2050000APPLICATION NO.
09/529,656APPLICANT
Wagner et al.102(e) DATE
June 22, 2000

GROUP

1642



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	8	Marumo, K., et al., "Application of the Interferon Minipellet to Human Renal Cell Carcinoma in Nude Mice," <i>Int. J. Urol.</i> 4:55-61 (January 1997).
	AS	8	Maulding, H.V., "Prolonged Delivery of Peptides by Microcapsules," <i>J. Controlled Release</i> 6:167-176 (1987).
	AT	8	Melief, C.J.M., et al., "Peptide-based Cancer Vaccines," <i>Curr. Opin. Immunol.</i> 8:651-657 (October 1996).

EXAMINER

DATE CONSIDERED

8/19/01


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.2050000APPLICATION NO.
09/529,659APPLICANT
Wagner *et al.*102(e) DATE
June 22, 2000GROUP
1643

642



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	Mellors, J.W., <i>et al.</i> , "Incorporation of Recombinant Gamma Interferon into Liposomes Enhances its Ability to Induce Peritoneal Macrophage Antitoxoplasma Activity," <i>Infect. Immun.</i> 57:132-137 (1989).
	AS	2	Morton, D.L., <i>et al.</i> , "Prolongation of Survival in Metastatic Melanoma after Active Specific Immunotherapy with a New Polyvalent Melanoma Vaccine," <i>Ann. Surg.</i> 216:463-482 (1992).
	AT	2	Pardoll, D.M., "Paracrine Cytokine Adjuvants in Cancer Immunotherapy," <i>Ann. Rev. Immunol.</i> 13:399-415 (1995).

EXAMINER

DATE CONSIDERED

8/19/01

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

NOV 09 2000

NOV 07 2000

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.2050000APPLICATION NO.
09/520,000APPLICANT
Wagner et al.102(e) DATE
June 22, 2000GROUP
1643

1642




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>10</u>	Perez, E.A., et al., "Weekly 24-hour Continuous Infusion Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma: A Phase I Study," <i>J. Immunother.</i> 10:57-62 (1991).
	AS	<u>10</u>	Porgador, A., et al., "Antimetastatic Vaccination of Tumor-bearing Mice with Two Types of IFN- γ Gene-inserted Tumor Cells," <i>J. Immunol.</i> 150:1458-1470 (1993).
	AT	<u>10</u>	Rosenberg, S.A., et al., "Experience with the Use of High-dose Interleukin-2 in the Treatment of 652 Cancer Patients," <i>Ann. Surg.</i> 210:474-485 (1989).

EXAMINER



DATE CONSIDERED

8/19/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

NOV 03 2000

Page 1 of 16

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0652.2050000

APPLICATION NO.
09/529,659

APPLICANT
Wagner *et al.*

102(e) DATE
June 22, 2000

GROUP
1643

TECH CENTER 1600-2000

NOV 07 2000

TRADEMARK OFFICE


U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>11</u>	Rosenberg, S.A., "Immunotherapy and Gene Therapy of Cancer," <i>Cancer Res.</i> 51(Supp 18):5074s-5079s (1991).
	AS	<u>11</u>	Rosenberg, S.A., <i>et al.</i> , "Initial Proposal of a Clinical Research Project," <i>Hum. Gene Ther.</i> 3:75-91 (1992).
	AT	<u>11</u>	Rosenberg, S.A., "Immunotherapy of Patients with Advanced Cancer Using Interleukin-2 Alone with or in Combination with Lymphokine Activated Killer Cells," in <i>Important Advances in Oncology</i> , V. de Vita, <i>et al.</i> , eds., J.B. Lippincott, Philadelphia, pp. 217-257 (1988).

EXAMINER



DATE CONSIDERED

8/19/01

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
 NOV 09 2000
 1642

FORM PTO-1449
 INFORMATION DISCLOSURE STATEMENT


ATTY. DOCKET NO.
 0652.2050000

APPLICATION NO.
 09/529,659

APPLICANT
 Wagner *et al.*

102(e) DATE
 June 22, 2000

GROUP
 4643



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	12	Rosenstein, M., <i>et al.</i> , "Extravasation of Intravascular Fluid Mediated by the Systemic Administration of Recombinant Interleukin 2," <i>J. Immunol.</i> 137:1735-1742 (1986).
	AS	12	Saravolac, E.G., <i>et al.</i> , "Effect of Liposome-encapsulation on Immunomodulating and Antiviral Activities of Interferon- γ ," <i>Antiviral Res.</i> 29:199-207 (March 1996).
	AT	12	Schmidt, W., <i>et al.</i> , "Cancer Vaccines: The Interleukin 2 Dosage Effect," <i>Proc. Natl. Acad. Sci. USA</i> 92:4711-4714 (1995).

EXAMINER

DATE CONSIDERED

8/19/01

EXAMINER: Initial ☒ reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

NOV 09 2000

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT


ATTY. DOCKET NO.
0652.2050000

APPLICATION NO.
09/529,659

APPLICANT
Wagner *et al.*

102(e) DATE
June 22, 2000

GROUP
1643-1642



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	13	Schmidt, W., <i>et al.</i> , "Transloading of Tumor Cells with Foreign Major Histocompatibility Complex Class I Peptide Ligand: A Novel General Strategy for the Generation of Potent Cancer Vaccines," <i>Proc. Natl. Acad. Sci. USA</i> 93:9759-9763 (September 1996).
	AS	13	Schweighoffer, T., <i>et al.</i> , "Adenovirus-enhanced Receptor-mediated Transferrin infection for the Generation of Tumor Vaccines," <i>Cytokines Mol. Ther.</i> 2:185-192 (September 1996).
	AT	13	van Slooten, M.L., <i>et al.</i> , "Liposomal Encapsulation of Cytokines to Achieve Paracrine Cytokine Delivery in Tumor Vaccine Development," <i>J. Liposome Res.</i> 8:118 (May 1998).

EXAMINER


DATE CONSIDERED

8/19/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

NOV 09 2000



<p>FORM PTO-1449</p> <p><u>INFORMATION DISCLOSURE STATEMENT</u></p>	<p>ATTY. DOCKET NO. 0652.2050000</p> <p>APPLICANT Wagner <i>et al.</i></p> <p>102(e) DATE June 22, 2000</p>	<p>APPLICATION NO. 09/529,659</p> <p>GROUP 3643 1642</p>
---	---	---

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	14	Zatloukal, K., <i>et al.</i> , "Elicitation of a Systemic and Protective Anti-melanoma Immune Response by an IL-2-based Vaccine. Assessment of Critical Cellular and Molecular Parameters," <i>J. Immunol.</i> 154:3406-3419 (1995).
	AS	14	Zatloukal, K., <i>et al.</i> , "Somatic Gene Therapy for Cancer: The Utility of Transferrinfection in Generating 'Tumor Vaccines,'" <i>Gene</i> 135:199-207 (1993).
	AT	14	Zier, K., and B. Gansbacher, "The Impact of Gene Therapy on T Cell Function in Cancer," <i>Hum. Gene Ther.</i> 6:1259-1264 (1995).

EXAMINER	DATE CONSIDERED 8/19/01
----------	-------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

NOV 09 2000



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 0652.2050000	APPRAISED 05/16/00
	APPLICANT Wagner et al.	
	102(e) DATE June 22, 2000	GROUP 1643 1642

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	15	Dialog file 351, unverified English language abstract of DE 44 11 425 A1, Document No. AP1, Derwent World Patents Index Accession No. 1995-367006/199548 (2000).
	AS	15	Dialog file 351, unverified English language abstract of DE 196 07 044 A1, Document No. AN2, Derwent World Patents Index Accession No. 1997-298108/199727 (2000).
	AT	15	Cleland, J.L., "Protein Delivery from Biodegradable Microspheres," Pharm. Biotechnol. 10:1-43 (1997).

EXAMINER 	DATE CONSIDERED 8/19/01
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

RECEIVED

NOV 09 2000

O I P E
Page 16 of 16

NOV 07 2000

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT


ATTY. DOCKET NO.
0652.2050000

APPLICATION NO.
78059829, 859, 33728

APPLICANT
Wagner *et al.*

102(e) DATE
June 22, 2000

GROUP
1643 1642




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	16	Fujioka, <i>et al.</i> , "Long-acting delivery system of interferon: IFN minipellet," <i>J. Controlled Release</i> 33:317-323 (1995).
	AS	16	
	AT	16	

EXAMINER

Paused

DATE CONSIDERED

8/19/01

EXAMINER: Initial #1 reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.